Our capabilities span the full spectrum of early-phase clinical and bioanalytical research, delivering seamless, end-to-end solutions for the accelerated market entry of your generic formulations and innovative therapies

Strategic Product Development & Consulting

Navigating the complex journey from formulation to market authorization requires a balance of strategic foresight and rigorous scientific precision. At MDL Clintech Limited, our Strategic Product Development and Consulting practice partners with pharmaceutical sponsors early in the product lifecycle to de-risk clinical pathways and streamline regulatory approval. We help define robust Target Product Profiles, offering critical guidance on bioequivalence pathways, reference listed drug (RLD) sourcing, and regulatory alignment across regional bodies like the PPB and EAC, as well as global health authorities and WHO Prequalification

Our core advantage lies in translating complex biopharmaceutics data into actionable development strategies. By conducting in depth risk assessments of critical formulation variables, evaluating Biopharmaceutics Classification System (BCS) profiles, and applying in vitro–in vivo correlation (IVIVC) principles, our scientific team forecasts pharmacokinetic outcomes before clinical dosing begins. This approach enables sponsors to optimize formulation performance and determine whether to pursue full in vivo testing or leverage cost-saving BCS-based biowaiver pathways

Ultimately, we deliver structured, cost- and time-efficient development roadmaps engineered to eliminate redundant trial iterations and protect R&D capital. By aligning clinical pharmacology study designs with sound statistical power modelling and clear regulatory milestones, MDL Clintech ensures every project progresses from formulation readiness to commercial dossier submission with speed, compliance, and predictable outcomes

BA/BE Study Execution

At MDL Clintech Limited, our clinical pharmacology infrastructure is purpose built to deliver high-precision Bioavailability (BA) and Bioequivalence (BE) evaluations that meet international GxP and ICH-GCP standards. We manage a comprehensive spectrum of Bioequivalence and Bioavailiabilty architectures, ranging from single-dose, multiple-dose, crossover, and parallel designs to complex fasting, fed, and steady-state evaluations. Our clinical units are fully equipped to handle diverse dosage forms, including conventional oral solids, complex modified- or extended-release systems, topicals, and oral solutions

Flawless execution is driven by our operational rigor and controlled clinical environment. Our dedicated clinical pharmacology unit operates with standardized dosing schedules, tightly controlled nutritional regimens, continuous biometric monitoring, and rapid, cold-chain-maintained biological sample processing. Every phase of trial conduct is overseen by experienced clinical investigators and medical monitors to ensure participant safety, protocol compliance, and absolute data integrity

Central to our study success is an extensive, well-characterized database of healthy volunteers. Supported by automated cross-checking systems, our recruitment workflows prevent multi-study overlap, verify mandatory wash-out periods, and maintain high participant compliance and retention rates. By combining sophisticated clinical capabilities with a reliable volunteer ecosystem, MDL Clintech ensures fast enrolment, on-time study completion, and audit-ready data for global regulatory submissions

Reference Listed Drug (RLD) Sourcing & Characterization

Securing the appropriate Reference Listed Drug (RLD) and validating its equivalence is the critical first hurdle in any successful Bioavailability and Bioequivalence (BA/BE) program. At MDL Clintech Limited, we provide end-to-end advisory on identifying, procuring, and legally sourcing authentic comparator products and reference standards across global and regional markets. We ensure the selected reference product aligns precisely with the regulatory mandates of your target health authorities, whether filing with regional agencies across Africa or pursuing global registrations

Beyond procurement, our scientific team designs and executes robust comparative characterization strategies prior to clinical dosing. We evaluate critical quality attributes of both test and reference formulations, including chemical purity, potency, solid-state stability, and in vitro dissolution kinetics across physiological pH media. By establishing baseline equivalence in the laboratory, we de-risk formulation differences, verify batch-to-batch consistency, and ensure your product enters clinical testing with predictable pharmacokinetic performance.

In Vitro–In Vivo Correlation & Formulation De-risking

Bridging laboratory data with clinical outcomes is essential to reducing the timeline and financial risks of drug development. At MDL Clintech Limited, our biopharmaceutics experts specialize in developing predictive and interpreting complex multi-media dissolution profiles, enabling sponsors to refine formulations before committing to full-scale clinical trials.

We work directly alongside formulation and R&D teams to diagnose and resolve critical bioavailability bottlenecks early in the lifecycle. Our team pinpoints whether absorption limitations stem from poor solubility, low permeability, or food-effect variables, while providing strategic guidance on release rates for modified- and extended-release dosage forms. Through this data-driven de-risking process, MDL Clintech helps pharmaceutical developers optimize batch-to-batch consistency, eliminate formulation failures, and ensure high confidence of bioequivalence in clinical testing

Regional Harmonization & Global Market Entry

Expanding into African and international markets demands a strategic regulatory approach that avoids redundant studies and shortens the path to approval. At MDL Clintech Limited, we guide pharmaceutical developers through the East African Community Medicines Regulatory Harmonization framework. By aligning clinical and bioequivalence study designs with harmonized regional guidelines, we enable sponsors to leverage a single, robust study dataset for simultaneous regulatory submissions across multiple member states, maximizing market reach while controlling development costs.

To ensure frictionless regulatory progression, our team provides complete pre-submission support, authoring comprehensive regulatory strategy dossiers and study rationales for national health authorities and institutional Ethics Review Committees. We actively prepare and participate in scientific advice and pre-submission meetings, pre-emptively addressing potential regulatory queries regarding study power, protocol architecture, and reference product justification. Through proactive alignment with regional and global standards, MDL Clintech secures clear, accelerated routes to product registration and market authorization.